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Trichostrongylus colubriformisThis review addresses the research landscape regarding vaccines against scour worms, particularly
Trichostrongylus spp. and Teladorsagia circumcincta. The inability of past research to deliver scour-
worm vaccines with reliable and reproducible efficacy has been due in part to gaps in knowledge con-
cerning: (i) host-parasite interactions leading to development of type-2 immunity, (ii) definition of an
optimal suite of parasite antigens, and (iii) rational formulation and administration to induce protective
immunity against gastrointestinal nematodes (GIN) at the site of infestation. Recent ‘omics’ develop-
ments enable more systematic analyses. GIN genomes are reaching completion, facilitating ‘‘reverse vac-
cinology” approaches that have been used successfully for the Rhipicephalus australis vaccine for cattle
tick, while methods for gene silencing and editing in GIN enable identification and validation of potential
vaccine antigens. We envisage that any efficacious scour worm vaccine(s) would be adopted similarly to
‘‘BarbervaxTM” within integrated parasite management schemes. Vaccines would therefore effectively par-
allel the use of resistant animals, and reduce the frequency of drenching and pasture contamination.
These aspects of integration, efficacy and operation require updated models and validation in the field.
The conclusion of this review outlines an approach to facilitate an integrated research program.
 2020 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastrointestinal nematodes (GINs) cost the Australian sheep
and goat industries approximately AUD 450 million per annum
(Lane et al., 2015), amounting to approximately 8% of the value
of the Industry. In Australia, and internationally, a significant pro-
portion of this cost is attributable to Haemonchus contortus (‘‘Bar-
ber’s pole worm”) and the combined impact of two other genera
of ‘‘scour worms”, including Teladorsagia circumcincta (‘‘small
brown stomach worm”) and Trichostrongylus axei (‘‘stomach hair
worm”) and small intestinal GINs, Trichostrongylus colubriformis
and Trichostrongylus vitrinus (‘‘black scour worms”). Several other
scour worms, including Nematodirus spp. (‘‘Thin-necked intestinal
worm”), Cooperia spp. (‘‘intestinal hair worms”), and the large
intestinal nematodes Chabertia ovina (‘‘large-mouth bowel worm”)
and Oesophagostomum spp. (‘‘large bowel worms”) add to the pro-
duction losses. Mixed infections are the norm, the proportional
compositions varying between countries, regions and enterprises.Successful integrated parasite management programs (IPMs)
(Kahn and Woodgate, 2012) involve the ‘‘prevention-detection-
response” approach where strategic use of anthelmintic treatments
is key alongside pasture management, breeding programs for
natural resistance or resilience, nutritional management, effective
diagnosis and drench efficacy testing. With growing concerns over
the re-emergence of widespread anthelmintic resistance in Tel.
circumcincta and T. colubriformis, and more erratic seasonal
weather, refugia-based strategies (e.g. targeted drenching) have
been introduced to IPM programs to prolong drench efficacy. Vac-
cines offer an optional and sustainable component of IPM
programs.
Vaccines have successfully controlled infectious diseases, utilis-
ing the host’s protective immune responsiveness to limit pathology
and production loss. The recent success of BarbervaxTM, which
achieves approximately 80% protection against H. contortus
through induction of high titres of antibody by repeated inocula
of a native gut antigen preparation (Le Jambre et al., 2008;
http://barbervax.com.au/), raises the possibility for vaccination
against other GINs. This may require the induction of an effective
mucosal immune response in these species which do not ingest
blood. With technological expansion in the development, design
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is likely that specific vaccines will need to be developed to control
each species, although a ‘‘pan-species” vaccine would be the ideal
product. To this end, this review has three aims:
(i) to review literature on scour worm vaccines to provide rea-
sons for the lack of (reproducible) success;
(ii) to examine new technologies and advances in the ‘omics’
areas which enable more incisive research into host-
parasite interaction, antigen identification, vaccine formula-
tion and delivery
(iii) to provide an integrated approach for the use of vaccines in
IPMs
2. Development of immunity to scour worms
2.1. Cross protection against GINs
Since most GINs infestations are mixed, many reports have
identified physiological and immunological regulation of parasites
in preferred niches in the GI tract in small ruminants with single
(bolus) or continuous (trickle) doses of infective L3s (iL3). Amongst
three abomasal GINs, combined infections reduced H. contortus by
50–90%, while Tel. circumcincta and T. axei were unaffected
(Dobson and Barnes, 1995). Gruner et al. (2002) studied popula-
tions of Tel. circumcincta and T. colubriformis in resistant (R) and
susceptible (S) rams, demonstrating that R ram lambs effected a
25% and 96% reduction in pasture L3 populations of Tel. circum-
cincta and T. colubriformis, respectively, after 2 years, consistent
with more effective immunity against T. colubriformis.2.2. Host-parasite interactions related to immunity
2.2.1. Induction and expression of immunity to scour worms
‘‘Resistance” to GINs is synonymous with the establishment of
innate and acquired immune responses. Resistance has a moderate
heritability (h2; see below), enabling selection for reduced faecal
worm egg counts (FWEC). Immunity is commonly assessed byFig. 1. Kinetics of the development of escalating immunity after infection of lambs dose
1990). Comparisons include: % L3 establishment (yellow (light grey)), egg production (areductions in FWECs, accompanied by larval differentiations (or
PCR) from faeces if the proportions of species are required; recent
development of nemabiome sequencing (metabarcoding) may
supercede this (Avramenko et al., 2015). When necropsies are per-
formed, immunity can also be expressed as reductions in total and
differential worm counts, worm length and the number of eggs in
the uterus.
‘‘Resilience” is usually defined as the ability of small ruminants
to thrive during field challenge with GINs. Resilience has a small
genetic component (h2  0.1) and is measured by liveweight gain,
fleece or meat production characteristics, and/or increased drench-
ing intervals (Bisset et al., 1996, 2001). The mechanism of resili-
ence is incompletely understood and resilient animals perform
less well under nutritional stress (MLA, 2017).
Development and expression of ‘‘conventional” immunity. In naïve
hosts, establishment rates for GIN range from 40% to 80% (Dobson
et al., 1990; Gaba et al, 2006). Initial losses of GIN are caused by
innate inflammatory responses, as establishment is enhanced by
pre-treatment with corticosteroids (Emery, 1996; Miller, 1996).
With continuous ingestion of iL3s, small ruminants develop an
age-related resistance to worm infestations (Fig. 1). The interval
of 4–9 weeks for the expression of immunity to T. colubriformis
L3s (Dobson et al., 1990) was similar to that observed in lambs
trickle infected with H. contortus L3s (Barger et al., 1985). The sea-
sonal ingestion of new cohorts of H. contortus L3s in Spring elicited
a ‘‘self-cure” reaction (Stewart, 1955; Blitz and Gibbs, 1972;
Adams, 1993) and eliminated other abomasal and intestinal GINs
(Stewart, 1955; Emery et al., 1993; Harrison et al., 1999). Sheep
immune to GIN that have been exposed within the previous
7 weeks can mount a ‘rapid rejection’ response that prevents
establishment of H. contortus L3s within 30 min (Miller, 1996)
and eliminates incoming T. colubriformis L3s from the entire 15 m
of the small intestine within 2 h (Wagland et al., 1996). While opti-
mal immunity removed GIN entirely (Wagland et al., 1996), lesser
levels of immunity resulted in establishment further downstream
in the small intestine (Harrison et al., 1999), indicating the reversi-
ble paralysis of motility by the ‘‘mucosal effector response” (Emery
et al., 1993; Harrison et al., 2008). The kinetics were accelerated in
genetically resistant sheep (Windon, 1996). The immune system ofd with 2000 Trichostrongylus colubriformis L3s per day (adapted from Dobson et al.,
s faecal worm egg count, red (medium grey)) and worm counts (blue (dark grey)).
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worm antigen to limit infections or reject worms. They may
remove worms with less collateral damage in the gut, or forage
better for dietary protein, which is essential for optimal develop-
ment of immunity to worms (Coop et al., 1995; van Houtert
et al., 1995).
At the mucosal surface, the development of protective immune
responses against T. colubriformis has been analysed through lapro-
scopic biopsy or sequential necropsy (McClure et al., 1992; Rowe
et al., 2009) with tissue or contents sampled through indwelling
abomasal or intestinal fistulae (Jones et al., 1994; Greer et al.,
2008; see Fig. 2 schematic). The expression of GIN immunity in
ruminants is consistent with a T helper 2 (Th2) response with pro-
duction of sensitized CD4+ lymphocytes expressing and secreting
interleukins IL5, IL13 and TNFa (Pernthaner et al., 2005b, 2006;
Ingham et al., 2008). Resistance to helminths in ruminants is asso-
ciated with increasing levels of parasite-specific IgG1, IgA, IgE
(Smith et al., 1983; Bendixsen et al., 2004; Pernthaner et al.,
2005, 2006; Shaw et al., 2009; Hein et al., 2010) mucosal mast cells
(MMCs) and eosinophils (Stewart, 1955; Emery, 1996; Emery et al.,
1993; Hein et al., 2010). These responses prevent L3 establishment
(Jones et al., 1994; McClure, 2000; Emery and Beveridge, 2015),
suppress egg production, and remove adult worms (McClure
et al., 1992). The levels of MMC sensitisation in the small intestine
are highest around the T. colubriformis establishment site (first
5 m), diminishing distally (Bendixsen et al., 1995), so that paral-
ysed worms may recover and establish further down the GI tract
(Harrison et al., 1999). However, unequivocal evidence of a protec-
tive immune response against T. colubriformis has only been
demonstrated for the carbohydrate larval antigen (CarLA) found
on many nematode L3s. The CarLA response, which prevents L3
establishment, can be measured and is speculated to avoid
‘‘immune-mediated scouring”, an untoward accompaniment to T.
colubriformis immunity in some Australian and NZ flocks
(Williams et al., 2010). This appears associated with eosinophilia
in the intestinal mucosa (Larsen et al., 1995) and a conventional
MMC-mediated rejection response.Fig. 2. Expanded schematic process for analysis of the dynamic development of host imm
the induction of protective host responses and the parasite antigens, stages or metabolic a2.2.2. Extrinsic inflammation and immunity to T. colubriformis
Several observations suggest that the induction of non-specific
‘‘allergic” inflammation in the small intestine may compromise T.
colubriformis L3 establishment by up to 50%. These include lectin-
containing navy beans in diets or i.p. inoculation of liposomes (D.
Emery, unpublished data), oral dosing with attenuated Salmonella
typhimurium aroA, and supplementation of diets with molybde-
num or n-6 or neutral lipids (McClure, 2000).
2.2.3. Immunity to T. circumcincta
As observed with trickle infections with other GIN, immunity in
lambs, dosed daily with 1000 Tel. circumcincta L3, develops from
4 weeks p.i. (Seaton et al., 1989), effectively regulating worm
growth and the control of worm establishment/survival. Regula-
tion of worm size and fecundity is strongly or causally associated
with IgA especially against L4 (Stear et al., 1995; Martínez-
Valladares, 2005; Strain et al., 2002). Eosinophil number is also
inversely associated with worm length and fecundity (Stear et al.,
2002), and eosinophils and IgA additively reduce worm growth
and fecundity. Eosinophils have been implicated in resistance to
infection with H. contortus (Meeusen and Balic, 2000; González
et al., 2011) and inoculation of soluble extracts of H. contortus L3/
T. colubriformis L3 into the mammary gland of immune and non-
immune ewes elicits, within 24 h, an exudate comprising >90%
eosinophils (Adams and Colditz, 1991).
The other major mechanism of resistance to Tel. circumcincta is
IgE and MMC-mediated control of establishment and survival
(Stear et al., 1995), alongside activation of pro-inflammatory
Th17 cells in the mucosa (Gossner et al., 2012). IgE activity against
iL3 seems to be most important (Sinski et al., 1995), preferentially
targeting defined molecules (Murphy et al., 2010).
2.3. Epidemiological and genetic influences on GIN immunity
Mucosal immune mechanisms are influenced by physiological
factors such as age, liveweight, pregnancy/lactation and sex, and
external factors such as nutrition and stress (McClure, 2000;unity during parasite maturation in vivo and ex vivo. The process aims to identify
ctivities which induce protection. EV, extracellular vesicles; ES, excretory secretions.
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worms is transient and requires relatively constant ingestion of
GIN to be maintained, as exemplified by volatility in anti-CarLA
IgA titres (Shaw et al., 2012) and the slow acquisition of age-
related resistance (Adams, 1993). Consequently, seasonal fluctua-
tions in the levels of pasture L3s, as well as drenching regimes,
delay the development of immunity in young lambs (Barger,
1988; McRae et al., 2015). Liveweight (nutrition/birth weight) also
presents an issue for GIN immunity, with a weaning weight of
23 kg the critical minimum for optimal survival rates and produc-
tion of Merino weaners in the face of GIN challenge (McClure and
Emery, 2007).
Resistance to GINs is a complex genetic trait influenced by
many genes and multiple non-genetic effects such as nutrition
and prior exposure. The heritability of a single FWEC generally
ranges between 0.1 and 0.4 which is sufficiently high to justify a
selective breeding programme. Multiple FWECs improve the heri-
tability. Alternative markers such as packed cell volume (Albers
et al., 1987), parasite-specific IgA (Strain et al., 2002) and salivary
IgA against CarLA (Shaw et al., 2012, 2013) may be cheaper to assay
and similarly heritable.
Several studies have demonstrated the feasibility of selective
breeding for resistance (Bisset et al., 2001; Woolaston and
Windon, 2001; Karlsson and Greeff, 2006), with current application
in commercial flocks in Australia, New Zealand and the UK. The
major concerns are balancing the relationship with productivity
and managing the transition to genomic selection. Mrode et al.
(2018) recommend a cost-benefit analysis for farmers in developing
countries to decide the most appropriate method of selection but
these also apply to sheep breederswith extensivelymanaged flocks.3. Vaccine design: adjuvants and immunostimulants for
ruminants
The variety of adjuvants (including ‘‘immunostimulants” and
‘‘immuno-enhancers”) available to veterinary vaccinologists
exceeds the limited array for human vaccines due to the various
degrees of tissue irritability from many preparations. For the
rational formulation of vaccines it is essential to understand the
chemistry, properties and activity of the various adjuvants
required to induce the desired protective response(s). For rumi-
nants, this field is moving from empiricism to precision, as under-
standing of immunity develops.3.1. Conventional adjuvants
Conventional veterinary adjuvants are either oil-based emul-
sions or other compounds, or combinations of both. The ‘‘type” of
oil influences the extent of tissue reactions, with muramyl-
dipeptide (MDP) in FCA causing large lesions which are not corre-
lated with antibody titres (Stewart et al., 1985). More recent oil-
based emulsions in the Montanide series (https://www.sep-
pic.com/montanide-range) are less irritating with more consistent
immunostimulation. Oil-based emulsions provide slow release of
antigen over months; removal of the injection site and regional
lymph node up to 3 months after vaccination caused significant
reductions and persistence of antibody (Lascelles et al., 1989).
Indeed, it was possible to achieve a heightened, antigen-specific,
IgG response by inoculating an unrelated soluble antigen into an
oil-based granuloma for up to 3 weeks after the initial s.c. injection
(D. Emery, unpublished data). The depot, slow-release effect was
consistent with a delayed but prolonged IFN-c response from the
draining lymph node, compared with shorter-acting adjuvants
such as QuilA (saponin, QS21), dextran sulphate (DXS) and
dodecyl-ammonium bromide (DDA) (Emery et al., 1990).A range of adjuvants has been evaluated in sheep (Tables 1, 2).
Most popular and well-characterised are the saponins (QuilA,
QS21), alhydrogel (AH) and DXS. Quil A and DXS given subcuta-
neously are acutely inflammatory, giving rise to short, sharp rises
in antibody and IFN-c responses (Emery et al., 1990). Given that
AH did not elicit IFN-c production after inoculation or from primed
lymphocytes (Emery et al., 1990), this adjuvant was presumed to
elicit a protective Th2-type response (Emery, 1996). To stimulate
ovine mucosal immunity, i.p. inoculation of incomplete Freund’s
adjuvant (IFA) was shown to stimulate intestinal immune
responses (Beh and Lascelles, 1981), inducing widespread, ectopic,
lymphoid aggregates in the mesentery.
The empirical nature of adjuvant use in ruminant GIN vaccine
development is reflected in the lack of data directly comparing
the effect of different adjuvants. Where comparisons exist, the
results are inconsistent. For example, using a native extract of H.
contortus, HcsL3, with Aluminium Phosphate induced significant
levels of protection against H. contortus challenge, but the effect
was abrogated when Quil A was added (Piedrafita et al., 2013).
For Hc23, protection was similar in groups vaccinated with the
antigen in Aluminium Hydroxide or Quil A, although Quil A alone
conferred some level of protection (González-Sánchez et al.,
2018). In contrast, vaccination of cattle against the abomasal para-
site Ostertagia ostertagiwith either native aspartyl proteinase (ASP)
or ES-thiol induced protection when formulated with Quil A but
not with Al(OH)3 (Geldhof et al., 2004; Gonzales-Hernandez
et al., 2016). Thus it appears that Th2-promoting adjuvants based
on aluminium salts are not always associated with optimal protec-
tion, necessitating empirical testing and comparison of adjuvants.
3.2. Alternative delivery strategies and formulations for mucosal
immunity
Substantial, and largely unsuccessful, efforts have been made to
develop adjuvants and/or delivery systems that can induce muco-
sal immune responses local to the site of infection. The most effec-
tive way is by administration of vaccines onto the mucosal surface
where antigen is primarily sampled by specialised cells (M-cells or
goblet cells) which deliver antigen to underlying dendritic cells
(DCs). In the case of M-cells, these localise to the follicle-
associated epithelium (FAE) overlying mucosa associated lym-
phoid tissue (MALT). DCs present antigen to T cells within MALT
or lymph nodes draining the mucosal site, to initiate the adaptive
immune response (Neutra et al., 2001). During this process, expres-
sion of tissue-specific adhesion molecules and chemokine recep-
tors are induced on activated T and B cells which allow
lymphocytes to recirculate to mucosal sites. In contrast, vaccines
delivered via s.c. or i.m. routes do not generally confer mucosal
homing on lymphocytes and therefore are less efficient in inducing
mucosal immune responses (McClure, 2008).
Mucosally-applied antigens face a formidable array of host
defences: they may be diluted in mucosal secretions or trapped
in mucus, excluded by epithelial barriers or agglutinating antibody
and, in orally administered vaccines, face large dilutions within the
rumen and degradation in the abomasum (McNeilly et al., 2008).
Furthermore, uptake of antigens in the intestine often results in
immune tolerance (Mayer and Shao, 2004). Mucosal vaccines must
therefore deliver adequate levels of antigen across the mucosal
barrier as well as activate appropriate signalling events to induce
adaptive immunity and not immune tolerance.
3.2.1. Route of delivery
Mucosally-primed lymphocytes also home to distant mucosal
sites, leading to the concept of the ‘‘common mucosal immune sys-
tem” (McClure, 2000). Given the challenges associated with oral
vaccines, the common mucosal immune system may be exploited
Table 1
Summary of vaccine trials for Teladorsagia circumcincta using native material and recombinant proteins.
Extract/Antigen Dose Route of vaccination Adjuvant % redn.
(eggs)
% redn.
(worms)
Reference
Mixed larval stage metabolites and ES from in vitro culture 300,000 larval
equivalents
i.m.
Orally (6 mth lambs)
FCA/IFA
none
81
76
44
46
Rose, 1976
i.m. (9 mth lambs) FCA/IFA 0 7 Rose, 1978
i.m. (3 mth lambs) FCA/IFA
none
57
47
60
48
Rose, 1978
Live mixed stage larvae from in vitro culture 50,000 larvae s.c. (6 mth lambs) none 37 44 Rose, 1976
Macerated worms L4/L5 from in vitro culture 30,000 larvae i.m. (6 mth lambs) FCA/IFA 44 66 Rose, 1978
L3 soluble somatic proteins 750 mg s.c. (5 mth lambs) Be(OH)2 –a 32 Wedrychowicz et al., 1992
Detergent (CTAB) extract of xL3 surface 750 mg s.c. (5 mth lambs) Be(OH)2 –a 72 Wedrychowicz et al., 1992
Detergent (CTAB) extract of xL3 surface 750 mg s.c. (5 mth lambs) FCA/IFA –a 31 Wedrychowicz et al., 1992
L3 antigen precipitated by IgA from lambs immunised with CTAB extract of xL3 surface 875 mg s.c. (5 mth lambs) Be(OH)2 –a 72b Wedrychowicz et al., 1995
L4 Con-A-binding fraction of a detergent-soluble membrane extract 34–48 mg i.m. (4 mth lambs) Quil A 29 –a Halliday et al., 2012
Oc-gal-GP (Peanut and ConA lectin binding fractions from Triton X-100 extracts) 140 mg i.m. Quil A 28 –a Smith et al., 2001
8 rec. antigen cocktail: Tci-APY-1; Tci-ASP-1; Tci-CF-1; Tci-ES20; Tci-MEP-1;
Tci-MIF-1; Tci-SAA-1; Tci-TGH-2
50 mg each protein s.c. in lambs 3-7 months
old at first vaccination
Quil A 70
58
0
14
49
52
0
47
30
55
56
15
3
67
64
46
74
50
Nisbet et al., 2013, 2019
s.c. in pregnant ewes Quil A 44 NDc Nisbet et al., 2016
4 rec. antigen cocktail: Tci-APY-1; Tci-CF-1; Tci-ES20; Tci-MEP-1 50 mg each protein combined s.c. (4.5 mth lambs) Quil A 0 0 Nisbet et al., Unpublished data
4 rec. antigen cocktail: Tci-ASP-1; Tci-MIF-1; Tci-SAA-1; Tci-TGH-2 50 mg each protein combined s.c. (4.5 mth lambs) Quil A 0 0 Nisbet et al., Unpublished data
2 rec. antigen cocktail: Tci-APY-1; Tci-MEP-1 50 mg each protein combined s.c. (6 mth lambs) Quil A 36
3
21
34
Nisbet et al., 2019
2 rec. antigen cocktail: Tci-mAPY-1d; Tci-MEP-1 50 mg each protein combined s.c. (6 mth lambs) Quil A 43 52 Nisbet et al., 2019
a Data not presented or not enumerated in manuscript.
b Note, ovalbumin also gave a 55% reduction in this experiment when administered with the same adjuvant.
c ND, not determined (ewes not euthanased).
d Loss of function mutant of Tci-APY-1 redn., reduction; mth, month; IFA, Incomplete Freund’s adjuvant; Be(OH)2, Berrylium hydroxide; rec., recombinant.
C.Britton
et
al./International
Journal
for
Parasitology
50
(2020)
533–
553
537
Table 2
Results of vaccine trials with Trichostrongylus colubriformis (Tc) extracts and antigens.
Extract/antigen Dose Route of vaccination Adjuvant % reduction (eggs) % reduction (worms)
Tc L3 Homogenatea 30,000–50,000 L3a JPP/rectal Cellulose
Chitosan
49–53
10–25
30
10
Post-exsheathment antigen (PEA) 100 IPP/IP Quil/AH 34 48
350 IPP/IP AH 32 nd
Soluble Protein TcL3a 5 mg rectal Cellulose 0 0
1 mg I/JPP AH 12 10
TcL3 pelleta 5 mg rectal Cellulose 0 0
Adult ES antigens 100 lg IP AH 52 47
ES 94 kDa 50 lg IPP AH <30 <30
ES 11 kDa 50 lg IPP AH <30 <30
ES 11 + 17 kDa or + 30 kDa 100 lg IPP AH 40 30–56
ES 30 kDa 50 lg IPP AH <30 <30
ES recombinant 17 kDa 250 lg
100 lg
33 lg
10 lg
3.3 lg
SC  2 Quil A 33
42
52
25
0
67
50
26
18
20
100 lg IP  2 AH
Quil A
IFA
AH-Quil A
46
0
15
24
32
ns
ns
ns
1 mg IPP  2 Aqueous
AH
Quil A
Dextran sulphate
Alginate
Fructose-1-P
IFA
Cellulose
34
43–62
42–53
66
39
57
41
37
3
24–57
26–41
37
28
13
19
47–71
1 mg Rectal PP  2 Cellulose
Chitosan
<30
<30
<30
<30
1 mg Pharyngeal LN 2 cellulose 0 0
ES recombinant 37 kDa 20–50 lg SC Quil A <25 <25
50 lg IP Aqueous
IFA
AH
Quil A
Dextran (DXS)
Ns
50
46
37–44
ns
Ns
nd
nd
nd
nd
100 lg
500 lg
100 lg
IPP-mucosa
JPP-mucosa
Rectal PP
Dextran-AH
IFA
AH
Quil A
AH
PLG Microspheres
Quil A
36
16
18
42
11
0
29
All
<30
Data from McClure (2008)a and Emery, McClure and Wagland (unpublished data).
jpp/ipp, jejunal and ileal Peyers Patches; AH, aluminium hydroxide (alhydrogel); IFA, incomplete Freunds adjuvant (Montanide: Marcol 52); PLG, poly-lactide-glycolide
microspheres.
Ipp, jpp were direct injections during laparotomy while rectal and mucosal routes involved delivery of vaccine to the luminal surface of the epithelium (McClure, 2000, 2008).
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ering antigens to accessible mucosal sites such as the terminal
rectum or nasal cavity, which are both rich in MALT. Several trials
where T. colubriformis antigens in either cellulose or chitosan gels
were delivered intra-rectally in sheep conferred some degree of
protection against subsequent challenge (McClure, 2008). Rectal
immunisation induced parasite-specific antibodies in the jejunum
which correlated inversely with FWECs and worm burden, pro-
viding evidence of a protective, common mucosal immune
response.
Intra-nasal vaccination of sheep with PP2Ar (a recombinant part
of the catalytic region of serine/threonine phosphatase 2A from the
hookworm Angiostrongylus costaricensis) together with Escherichia
coli bacterial cell walls induced protection against H. contortus
and Tel. circumcincta, and intra-nasal vaccination of pigs and mice
with recombinant Ascaris suum antigens reduced numbers of lar-
vae recovered from the lung (Tsuji et al., 2001, 2003, 2004). These
studies demonstrate the potential of intra-nasal vaccination to
control GINs, although A. suum vaccines could operate in the intes-
tine, lung or on migratory stages.3.2.2. Live vectors
The efficacy of live vectors in mucosal vaccines is largely due to
their ability to survive the luminal environment, actively invade
mucosal tissues and trigger appropriate immune responses. For
nematodes, most work on live mucosal vaccines has been con-
ducted using attenuated strains of Salmonella typhimurium in mice.
In these studies, oral or intra-nasal delivery of attenuated S. typhi-
murium expressing a number of Trichinella spiralis antigens elicited
robust Th1/Th2 and mucosal IgA, and conferred protection against
subsequent T. spiralis infection (Yang et al., 2010; Pompa-Mera
et al., 2011; Liu et al., 2015; Wang et al., 2016). However, there
are some concerns over safety and stability, and their efficacy in
the face of pre-existing immunity to the vector.3.2.3. Particulate delivery systems
Formulation of antigens into particles should protect the antigen
from degradation and increase uptake by MALT. Enhanced uptake
of microparticles is largely by M-cells which efficiently take up par-
ticles of <1 mm diameter. Little research has been conducted on the
use of microparticles in nematode vaccines but, in mice, oral deliv-
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mers successfully induced mucosal IgA responses and protection
against parasite challenge, indicating the potential utility of the
approach (Dea-Ayuela et al., 2006). Microparticles have been tested
in sheep including poly(D,L-lactide-co-glycolide) microparticles to
deliver Toxoplasma gondii antigens intranasally (Stanley et al.,
2004), and ISCOMs, 40 nm nanoparticles, to deliver viral antigens
orally or intranasally (van Pinxteren et al., 1999; Coulter et al.,
2003). Mucosal ‘targeting’ peptides, which facilitate transcytosis
of conjugated molecules across the sheep intestinal epithelium to
DCs in the lamina propria and Peyer’s patches, may enhance intesti-
nal microparticle uptake by incorporating these targeting peptides
into particulate delivery systems (Kenngott et al., 2016).
3.2.4. Mucosal adjuvants
Induction of adaptive immune responses to inert mucosally-
delivered antigens usually requires co-delivery of mucosal adju-
vants e.g. Cholera Toxin (CT) and E. coli heat-labile toxin (LT). Only
CT has been tested in sheep and induced mucosal IgA following
rectal and intranasal delivery (Jacobs et al., 1999; Premier et al.,
2004; Stanley et al., 2004). Chitosan gels used to deliver T. colubri-
formis antigens rectally possess adjuvant properties (McClure et al.,
2008), and ISCOMs have adjuvant properties as they are largely
from the adjuvant Quil A (Morein et al., 2004). Toll-like receptor
(TLR) ligands such as bacterial flagellins (Lee et al., 2006;
Meeusen et al., 2013) and CpG (Gallichan et al., 2001) have also
been successfully used as mucosal adjuvants, but not yet in sheep.
3.3. Induction of Th2 responses in sheep
In sheep models of allergic asthma, SC immunizations with
ovalbumin (Abraham, 2008; Abraham et al., 1983), peanut allergen
(Van Gramberg et al., 2012) and dust mite allergen (HDM), with
alum adjuvant (Bischof et al., 2003) have successfully induced
antigen-specific IgE. In the dust-mite model, 50 mg of HDM
resulted in approximately 60% of sheep developing high levels of
HDM-specific serum IgE. Experimentally sensitized sheep segre-
gated into high and low IgE responders to HDM, and those with
high specific IgE serum titres (allergic sheep) generated an elevated
and prolonged broncho-alveolar lavage (BAL) containing eosino-
philia when challenged with HDM (Bischof et al., 2003). This would
suggest that if antigen-specific IgE responses provided protection
against GIN, these protocols could be used to induce Th2 responses
in sheep mucosa.
Manyparasite infections induce a Th2 responsewith elevated IgE
(see Shawet al., 2009). Following T. colubriformis challenge, immune
animals had higher levels of total IgE in intestinal lymph than non-
immune sheep, low FWEC sheep had higher concentrations of total
IgE thanhighFWECsheep, andfield-primedanimalshadhigher total
IgE levels thanGIN-naıve animals, arising from stage-specific induc-
tion of IgA and IgE responses in regional mesenteric lymph nodes
(MLNs) (Pernthaner et al., 2006). Similar observations have been
made following Tel. circumcincta challenge where IgE responses to
L3 but not adult antigenswere detected in abomasal lymph samples
from immune versus non-immune sheep (Huntley et al., 1998).
Serum IgE obtained from high and low FWEC lambs bound to west-
ern blotted T. colubriformis L3 antigens of 40 (galectin), 31 (Aspin)
and 21 kDa (Shaw et al., 2013; Bendixsen et al., 2004). Levels of
specific IgE to T. colubriformis L3-excretory-secretory antigens (ES)
was heritable (h2 = 0.36) and showed a negative genetic correlation
with FWEC (ca 0.31; Shaw et al., 1999). IgA titres to CarLA were
both moderately heritable (0.28 ± 0.10) and negatively correlated
with FWECs (0.57 ± 0.20; Shaw et al., 2013).
Induction of Th2 responses has been attempted by various
routes, but the precise role of IgE in protection is still unresolved.
What is clear is that: antigens on parasites recognised by IgE or IgA from immune
animals do not possess intrinsic ‘‘allergic” potential – they do
not readily generate IgA or IgE when presented in purified or
recombinant- adjuvanted forms;
 formulations which induce Th2 responses in rodent models do
not reliably extrapolate to ruminants; and,
 vaccine formulations which induce mucosal Th2 responses in
ruminants are not readily available.
While induction of Th1 immunity is largely understood, the
mechanisms underlying initiation of Th2 immunity have been
unclear until recently. Studies in murine nematode infections indi-
cate a critical role for epithelial tuft cells in the initiation of Th2
immunity to GIN (Gerbe et al., 2016; Howitt et al., 2016; von
Moltke et al., 2016). Tuft cells appear to be the primary source of
the Th2 alarmin, IL-25, which activates innate lymphoid cells
(ILC); ILC2-derived IL-13 acts in a positive feedback loop to expand
tuft cell numbers. Once sufficient IL-25 and IL-13 are generated,
Th2 immunity is induced. Putative tuft cells have been identified
in sheep and expand during Tel. circumcincta infection in a similar
manner to that observed in mice (K. Hildersley, C. Britton, T.N.
McNeilly et al., unpublished data). As tuft cells are chemosensory,
it is possible that their activation to produce IL-25 is through sens-
ing ‘helminth-associated molecular patterns’, or molecules indi-
rectly induced in the gut lumen following parasite infection. If
identified, these tuft cell activating molecules could be used as
adjuvants to drive more effective Th2 immunity.
3.4. Immune modulators for redirection of systemically induced
immune responses to mucosal surfaces
Specific adjuvants for systemically delivered vaccines which
target the immune response to mucosal sites have not yet been
widely exploited in small ruminants. However, vitamin D3 in sys-
temically delivered subunit vaccines induces mucosal antigen-
specific IgA responses in mice, pigs and cattle (Daynes et al.,
1996; Van der Stede et al., 2001; Vilte et al., 2011). Other examples
include TLR ligands, poly I:C (TLR3 ligand), lipopolysaccharide
(LPS), (TLR4 ligand), and flagellin (TLR5 ligand), which induce
mucosal IgA following systemic delivery (Enioutina et al., 2008;
McNeilly et al., 2008,). TLR3 and TLR4 upregulated 1a-
hydroxylase in DCs which converts circulating 25(OH)D3 to cal-
citriol, the active form of vitamin D3. Interestingly, TLR3 and
TLR4 ligands were capable of inducing IgA to co-administered sol-
uble antigens, whereas for the TRL5 ligand flagellin, IgA responses
were directed towards flagellin but not the co-adminstered anti-
gens (McNeilly et al., 2010), suggesting a need for physical linkage
of antigen and TLR ligand for IgA induction. Exploiting vitamin D,
either by direct inclusion into systemically delivered vaccines or
incorporation of TLR ligands which upregulate vitamin D activity,
or incorporating other TLR ligands into antigen-containing
microparticles, may be a useful approach to enhance mucosal
immune responses in nematode vaccines.
4. GIN vaccines for scour worms - antigen discovery and types of
vaccines
There are five main categories of vaccines for the control of
pathogens in humans and livestock:
(1) chemically abbreviated infections (‘‘truncated” infections);
(2) pathogens attenuated by irradiation or culture (or use of
closely-related, less pathogenic organisms);
(3) protein subunit/nucleic acid subunit vaccines – (native pro-
teins, protein complexes or recombinant subunits);
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(5) toxoids – inactivated compounds where these (rather than
the organisms) cause disease.
The successful development of vaccines against GIN has
focussed on the first three categories.
Examination of naturally-acquired immunity against the princi-
pal GINs of small ruminants indicates that the most vulnerable
stage is iL3, through reduced establishment rates (Barger et al.,
1985; Dobson et al., 1990) or larval development (Seaton et al.,
1989). Expulsion occurs in a common time-frame and effector
mechanism (Stewart, 1955; Emery et al., 1993; Harrison et al.,
1999). The L3 stage of GIN parasites would be the most obvious
target, negating the pathology associated with later stages of worm
development and expulsion (Barker, 1975; McKellar, 1993; Stear
et al., 2003; Greer et al., 2008; MLA, 2017). However, since low
doses of iL3s can subvert established immunity (Smith et al.,
1983; Dobson et al., 1990), information on protective immunogens
from later stages of GINs is pivotal for rational vaccine
development.
Natural immunity against GINs is rarely ‘‘sterile”. Under natural
conditions with low dose challenge, some worms establish even in
immune animals (Smith et al., 1983). Three thousand to 4500 iL3s
is considered a threshold to ignite the immune response (Dobson
et al., 1990). Comparatively, GIN with developmental stages in tis-
sues (i.e. Tel. circumcincta, O. columbianum) are more vulnerable to
suppression/retarded development than those residing on the
mucosa.
4.1. Chemically abbreviated (truncated) infections
Chemically abbreviated infections have been used to investigate
protective immunity. Repeated rounds of T. colubriformis infection
(3 infections of 30,000 iL3) generated solid resistance to homolo-
gous L3 and adult worms in hoggets, rejection occurring within 3–
5 days (Emery et al., 1992a). Sheep given similar 4  7 days and
4  10 days larval infections rejected T. colubriformis L3 challenge
but rejected only 50% of adult worms while sheep given 4  4 days
infections remained fully susceptible. This indicated that stage-
specific antigens produced by early L3 and L4 stages effectively
immunized sheep, while sheep immunised with adoptively trans-
ferred adult worms took 7–10 days to reject the iL3 challenge, pre-
sumably when adult antigens were produced (Emery et al., 1992b).
Such approaches proved less successful in 1 month old lambs
(McClure et al., 1998). However, similar truncated infections also
induced >90% protection against T. colubriformis ingested from pas-
ture (Stankiewicz et al., 1996; Harrison et al., 2003), with
‘‘immunity-induced” weight loss associated with increased levels
of gut eosinophils (Stankiewicz et al., 1996). This approach was
unsuccessful against homologous Tel. circumcincta challenge
(Harrison et al., 2003) but successful against H. contortus
(Robinson et al., 2010).
McClure (2008) administered 18 doses of 1200 T. colubriformis
L3 (in cellulose gel; three per week for 6 weeks) to the rectal lym-
phoid tissue and mucosa, generating >88% protection against a
challenge infection of 30,000 L3, demonstrating additional routes
of vaccination other than oral or IP (see Section 4.2).
4.2. Radiation-attenuated vaccines
Following the successful immunisation of calves against bovine
lungworm (Dictyocaulus viviparus) using two doses of 1000 irradi-
ated L3s (Jarrett et al., 1959; later Dictol), Dineen et al. (1978)
used irradiated T. colubriformis L3s to select Merino weaner lambs
into resistant and susceptible genotypes. Successive generations of
the model were used to elucidate the mechanisms of GIN resis-tance. While this approach successfully segregated response phe-
notypes, the 2  20,000 L3 vaccination protocol was unrealistic
for the field. Immunisation of sheep >7 months old with irradiated
H. contortus L3 or T. colubriformis L3 conferred high levels of protec-
tion against homologous challenge (Jarrett et al., 1961; Dineen
et al., 1977; Smith and Christie, 1978; reviewed by Bain (1999)).
In trials with Tel. circumcincta, 8 month old Greyface-Suffolk
cross sheep were immunised with two doses of 10,000 gamma-
irradiated iL3 4 weeks apart and then challenged, 4 weeks later,
with a bolus of 10,000 non-irradiated iL3ss (Smith et al., 1982).
Four weeks after the challenge dose, adult worm burdens of immu-
nised sheep were 60% lower (P < 0.05) than controls and peak
FWEC was reduced by 65% (Smith et al., 1982). When irradiated
worms were removed by anthelmintics 1 week before challenge,
the protective effect was lost, demonstrating the need for concomi-
tant infection with the irradiated larvae for protection (Smith et al.,
1982). Similar levels of protection have also been demonstrated by
immunising 3–5 month old lambs with two oral doses of 50,000
Tel. circumcincta L3s attenuated by UV irradiation Wedrychowicz
et al. (1992).
4.3. Native antigen-based vaccines
4.3.1. Parasite extracts
Barbervax Gut membrane preparations of Haemonchus con-
taining glycoprotein complex H-gal-GP and aminopeptidase H11
have consistently conferred protection against homologous chal-
lenge (Le Jambre et al., 2008). These antigens, in microgram quan-
tities, conferred high levels of protection, allowing the commercial
exploitation of a native vaccine (reviewed in Nisbet et al., 2016a).
The antigens present in Barbervax are ‘‘concealed” so, in the
absence of exposure-related boosting of the immune response,
repeated vaccination is required to stimulate high antigen-
specific circulating antibody levels. An advantage of these con-
cealed antigens is that they can produce protective effects in situa-
tions where natural immunity is either weak or ineffective, such as
in young lambs or in periparturient ewes (Le Jambre et al., 2008).
Teladorsagia circumcincta. Table 1 summarises trials using either
native or recombinant Tel. circumcincta antigens. Immunisation of
5 month old Finn-Dorset male lambs with a detergent extract of
exsheathed L3 (surface antigens) formulated with Beryllium
hydroxide adjuvant, followed by challenge with a bolus of 50,000
iL3, resulted in parasite burdens which were significantly reduced
(by 72%, P < 0.01) compared with non-immunised controls
(Wedrychowicz et al., 1992, 1995). Somatic extracts of L3 in the
same adjuvant gave only modest reductions in worm burden
(30%) compared with control lambs (Wedrychowicz et al., 1992).
In contrast, somatic extracts of L4/early L5, administered to
6 month old Dorset Horn lambs by repeated injection in FCA/IFA
over a 3 week period, induced protection (66% reductions in adult
worm burden, 44% reduction in FWECs) when challenged with a
trickle infection of 5000 iL3s daily over a 15 day period (Rose,
1978).
Immunisation of 2 month old Suffolk-Greyface cross lambs with
H. contortus H11 and H-gal-GP conferred no cross–protection
against Tel. circumcincta (Smith et al., 2001). When 9 month-old
Suffolk-Greyface sheep were immunised with lectin-binding inte-
gral membrane glycoproteins derived from adult Tel. circumcincta,
with Quil A, and challenged with a bolus of 5000 iL3s Tel. circum-
cincta, worm burdens and FWECs were reduced by only 8% and
28%, respectively, compared with control, adjuvant-only recipients
(Smith et al., 2001). As immunisation had induced high levels of
circulating antibodies, it was concluded that adult Tel. circumcincta
did not consume sufficient antibody for the gut antigen approach
to be effective (Smith et al., 2001). Based on the hypothesis that
L4 Tel. circumcincta induce more localized inflammation at the site
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quantities of ingestible immunoglobulin, Halliday and Smith
(2011) immunised 4 month old Scottish Mule lambs with lectin-
binding integral membrane glycoproteins derived from L4 Tel. cir-
cumcincta, with Quil A, and challenged the lambs with either a
bolus (5000 iL3) or trickle (500 iL3s daily for 10 days) Tel. circum-
cincta challenge. No significant reductions were observed in either
FWECs or worm burden with either challenge method (Halliday
and Smith, 2011).
Trichostrongylus colubriformis. Table 2 summarises vaccine trials
with a range of antigens and preparations from T. colubriformis.
From initial screens in the guinea pig model and the premise that
surface or ES antigens shed from various parasitic stages contribute
to protective immunity observed with trickle iL3s infections
(Dobson et al., 1990), L3 homogenates, post-exsheathment antigen
(PEA) and native adult ES antigens were employed. Animals were
challenged with trickle infections of 1500–2000 L3s, 3  weekly
for 3 weeks. Larval homogenates and soluble proteins, PEA and
post-extraction iL3s pellets in a variety of adjuvants failed to gen-
erate consistent protection (>57%) when administered either s.c., i.
p., inoculated into intestinal Peyers Patches (JPP/IPP) or when in
cellulose gels applied to the rectal mucosa (McClure, 2008).
Throughout these trials, antigens incorporated into AH, which did
not elicit IFN-c (Emery et al., 1990), generated higher levels of
immunity than other adjuvants.
4.3.2. ES antigens
Trichostrongylus colubriformis. Adult T. colubriformis produce
1 mg of ES protein per 25,000 worms daily (unpublished observa-
tions). Early vaccine trials, using L3 soluble proteins (SpL3) or ES
antigens from L3 or adult worms gave >90% reductions in worm
counts in a guinea pig infection model (Rothwell et al., 1994).
The protection was reduced if ES proteins were administered in
FCA instead of AH (Wagland et al., 1996). Subsequent comparisons
in sheep were less successful; worm burdens reduced by 30–70%
when adult ES material (1 mg/dose) was used (see Emery, 1996;
Table 2).
Teladorsagia circumcincta. Early vaccine trials using ES material
from mixed stage Tel. circumcincta, administered in FCA/IFA to
9 month old cross bred lambs repeatedly over a period of 3 weeks
followed by a trickle infection of 5000 L3 daily for 15 days, gave no
reductions in either FWECs or worm count (Table 1) (Rose, 1978).
In contrast, when 3 month old Dorset Horn lambs were immunised
with concentrated ES from mixed stage Tel. circumcincta (with or
without FCA/IFA) and challenged by a trickle infection of 7500
L3s per day for 4 days, immunised lambs had between 48% and
69% fewer adult worms and reductions in FWECs of 47% to 60%
compared with controls (Rose, 1978).
4.3.3. CarLA (Carbohydrate Larval Antigen)
Harrison et al. (2003) isolated a heat-stable 35 kDa carbohy-
drate antigen (CarLA) when T. colubriformis L3 extracts were
probed with sera from GIN-immune sheep and /or genetically
resistant animals. The antigen was shared by a range of GIN,
including H. contortus, Tel. circumcincta and Nematodirus. CarLA
was poorly immunogenic, and a range of coupling agents were
examined to attempt to boost its immunogenicity. Although the
antigen was not tested directly as a vaccine, indirect evidence of
its putative protective capacity was inferred from the inhibition
of establishment of T. colubriformis which had been pre-
incubated with immune mucus before dosing to sheep (Harrison
et al., 2003). Interestingly, while anti-CarLA Ig in immune mucus
inhibited T. colubriformis establishment, H. contortus and Tel. cir-
cumcincta were virtually unaffected (Harrison et al., 2008). It was
later demonstrated that H. contortus possessed different isoforms
of CarLA, and that mucus isolated from sheep immunised withHaemonchus or Teladorsagia CarLA did not generate high levels of
anti-CarLA antibodies (Harrison et al., 2008). However, titres of
anti-CarLA IgA, although transient, are indicative of worm immu-
nity (Shaw et al., 2012).
4.4. Recombinant antigen vaccines
The development of recombinant subunit vaccines for the pro-
tection of small ruminants against GIN has been, until recently, rel-
atively unsuccessful (McClure, 2009; Nisbet et al., 2016a;
Matthews et al., 2016; Stutzer et al., 2018). Recent work to develop
a recombinant subunit vaccine for Tel. circumcincta has shown
some promise in both lambs (Nisbet et al., 2013) and periparturi-
ent ewes (Nisbet et al., 2016b).
4.4.1. Teladorsagia circumcincta
Previous evidence of the underlying immune mechanisms act-
ing against the parasite (Smith et al., 1985, 1986, 1987), was used
to select L3 and L4 ES proteins which were targets of local IgA
responses in immune sheep. Bioinformatic analysis (Nisbet et al.,
2008) also identified an immunogenic homologue of a protective
antigen of the canine hookworm, Ancylostoma caninum (Ac-SAA-1
(Zhan et al., 2004; Nisbet et al., 2009)); and potential immunosup-
pressive molecules released by the parasite were also identified
(McSorley et al., 2009; Nisbet et al., 2010, 2011). The eight vaccine
candidates identified using this tripartite approach were prepared
as a recombinant cocktail vaccine and formulated in Quil A. In
Texel-cross (6–7 month old) lambs, in two separate trials, this pro-
totype cocktail vaccine reduced cumulative FWECs (cFWECs) by
70% and 58% compared with control lambs which received adju-
vant only (Nisbet et al., 2013). The parasite challenge in each of
these experiments was a 4 week trickle infection and, during the
period of peak worm egg shedding, vaccinated lambs shed 92%
and 73% fewer eggs than control lambs. Vaccinates had 75% and
56% lower mean adult nematode burdens than controls (Nisbet
et al., 2013).
Using the same vaccine to immunise lambing ewes resulted in a
44% reduction in mean cFWECs levels compared with ewes given
adjuvant only (Nisbet et al., 2016b). More recently, Nisbet et al.
(2019), used data from five independent vaccine trials with this
cocktail vaccine, to simplify its antigenic complexity. This meta-
analysis demonstrated statistically significant reductions in FWECs
and worm burden in vaccinated sheep across trials (P = 0.009 and
P < 0.0001, respectively). Relationships between antigen-specific
antibody (IgA; total IgG; IgG1 and IgG2) levels, antibody avidity
and parasitological parameters of efficacy were analysed for each
of the eight proteins in these trials. The strongest correlations
between percentage reduction in cFWEC and avidity were obtained
for Tci-APY-1 (a calcium-dependent apyrase). The inclusion of Tci-
APY-1 in a simplified vaccine was further supported by the obser-
vation that serum and mucosal IgG and IgA of control (parasite
challenged) lambs strongly recognised Tci-APY-1 as well as a fur-
ther vaccine antigen, Tci-MEP-1. A two-protein vaccine (Tci-APY-
1 and Tci-MEP-1) was tested in a direct comparison with the orig-
inal eight-component vaccine (Nisbet et al., 2019). In the same
experiment, a further group was immunised with Tci-MEP-1 plus
a mutated form of Tci-APY-1 (mTci-APY-1), which had no enzy-
matic activity. The rationale behind the inclusion of a loss-of-
function mutant apyrase was that a previous study demonstrated
that transient ATP release at the injection site is required for opti-
mal efficacy of some adjuvants and that inclusion of an active apyr-
ase into an adjuvanted influenza vaccine led to inhibition of innate
and adaptive responses, presumably due to hydrolysis of extracel-
lular ATP (Vono et al., 2013).
Across the timeframe of the trial, the FWEC levels of the eight-
antigen recipients were consistently lower than those of the adju-
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mTci-APY-1 and Tci-MEP-1 recipients was lower (43%), although
not statistically significantly (P = 0.079), than that of the controls
(Nisbet et al., 2019).
4.4.2. Trichostrongylus colubriformis
Several adult ES proteins expressed in E. coli or baculovirus (11,
17, 30, 37 and 94 kDa) have been investigated as protective
immunogens in sheep (McClure, 2008; Frenkel et al., 1992;
Table 2). A series of trials were undertaken, using adjuvant combi-
nations and targeting mucosal delivery routes (IP, Peyer’s Patches
and rectal mucosa) to sensitise MMC and generate worm-specific
IgG1, IgA and IgE (Emery, 1996; McClure, 2008). Table 2 lists much
unpublished work to prevent repetition of past efforts. Overall,
these antigens and protocols failed to generate >70% protection.
However, there was little doubt that mucosal vaccination, espe-
cially through IPP and JPP using antigens in AH, effectively gener-
ated antigen-specific IgG1, IgA and IgE responses.
4.5. Novel expression systems
A major hurdle in vaccine development is expression of vaccine
candidate genes in appropriate expression systems. Genes from Tel.
circumcincta and H. contortus can be expressed in Caenorhabditis
elegans and can rescue C. elegans mutant phenotypes, demonstrat-
ing correct folding and functional activity (Britton and Murray,
2006; Baker et al., 2012). While C. elegans may be appropriate for
expression of some parasite proteins, our group were unable to
express H. contortus vaccine antigen H11 or cysteine or aspartyl
proteases in C. elegans in a form that can induce protection
(Roberts et al., 2013). This suggests that a combination of antigens
is required to induce immunity or, alternatively, specific glycans
present on H11 and other vaccine antigens are needed and are
not present on C. elegans expressed proteins. Detailed mass spec-
trometry comparison of glycans present on native H. contortus
H11 and C. elegans-expressed recombinant H11 identified similar
di- and trifucoslyated glycans but there was a lack of fucosylated
LacdiNAc (LDNF) and Gala1-3GalNAc structures on C. elegans
recombinant H11 (Roberts et al., 2013). The use of synthetic gly-
cans as vaccines would help test the relevance of glycan structures
to protection (Astronomo and Burton, 2010).
Where glycans and other post-translational modifications intro-
duce conformational epitopes, these can be extremely challenging
to reproduce in a recombinant expression system. One approach is
to use commercially available random peptide phage-display
libraries to identify short peptide epitopes that are bound by anti-
bodies from immune animals. These phage-displayed peptides
may represent primary protein sequence or more complex sec-
ondary or tertiary structural epitopes, and may even mimic non-
peptide components such as carbohydrate moieties. Phage-
displayed peptides have been used in the development of proto-
type vaccines against a range of parasites including T. spiralis (re-
viewed in Ellis et al., 2012). Preliminary work using antibodies
from sheep immune to Tel. circumcincta to pan phage-displayed
peptide libraries identified five peptide sequences which mimicked
surface and/or glycan epitopes on exsheathed L3s (Ellis, 2014.
Interactions of Teladorsagia circumcincta with the ovine immune
system – mimicry and vaccine development. PhD Thesis, Univer-
sity of Edinburgh, Scotlan.). Positive correlations were demon-
strated between peptide-specific IgA levels for these five
peptides, and the percentage of inhibited L4s in the abomasum,
whereas there were negative correlations between the levels of
peptide–specific IgA and total nematode burden (Ellis, 2014, cited
above).
Plant expression systems can produce high levels of protein in
soluble, secreted form, technology to manipulate their glycosyla-tion machinery is available and they are being tested for expres-
sion of parasite proteins, particularly those where folding and/or
glycosylation are critical for function or immunity (Wilbers et al.,
2017). Transgenic tobacco has been used to determine the struc-
ture and binding properties of nematode venom allergen-like pro-
teins (VALs) (Asojo et al., 2018; Darwiche et al., 2018). A similar
approach would be valid for testing expression, function and pro-
tective capacity of related ASPs and other vaccine candidates from
scour worms.5. Technological advances and opportunities (and how they can
be used)
5.1. Current status of worm assays
There are limitations for the in vitro cultivation of GIN. While
exsheathed Haemonchus L3 develop to L4 in simple medium, more
complex conditions are needed for development to adults
(Douvres, 1980; Stringfellow, 1986). Consequently, researchers
have relied on supplies of iL3, or parasites at various stages of
development ex vivo (eg. Rowe et al., 2008; McNeilly et al.,
2017), to measure viability, egg production or comparative mea-
surements of length or sex ratios (eg. Rowe et al., 2008; McNeilly
et al., 2017). In vitro studies on immunity have relied primarily
on the Larval Development Assay (LDA; Lacey et al., 1990) or paral-
ysis of L3 motility in various ‘‘wriggle-ometers”, with or without
downstream ‘omics’ investigations (Jones et al., 1994; Hu et al.
2013,). RNA interference (RNAi) and functional validation studies
have used short-term cultures, with assay of the target gene, its
transcription or products (Kotze and Bagnall, 2006) or worm sur-
vival in vivo (Samarasinghe et al., 2011). Progress in this area
would greatly assist vaccine development and antigen validation.
5.2. Antigen identification from genomic and transcriptomic data
Vaccine candidate identification has relied mainly on the use of
antisera from immune or convalescent animals to screen either
cDNA libraries or immunoblots for immunodominant antigens
(e.g. Verkuylen et al., 1993; Redmond et al., 2006) or in
immunoaffinity purification (e.g. Ellis et al., 2014). However, over
the last decade information on the complete set of genes present
in parasitic nematodes, the lifecycle stages in which these genes
are expressed and detail of their putative functions, has greatly
increased. This allows rational selection of potential vaccine tar-
gets including enzymes catalyzing unique metabolic pathways,
secreted and surface proteins, and immunoregulatory molecules.
Comparing genomes across species will establish a map of genes
conserved across diverse nematodes, to help identify biological
function and reveal potential pan-nematode targets.
5.2.1. Genomics and transcriptomics
Genomic data is available for a range of nematodes, including
many of veterinary importance. A comparative genomics analysis
of 56 nematode species, including H. contortus and Tel. circum-
cincta, has recently been published (International Helminth
Genomes Consortium, 2019), supported by the 50 Helminth Gen-
omes project (https://www.sanger.ac.uk/science/collaboration/
50hgp). Progress has been helped by the reduced cost of sequenc-
ing, together with improved technologies and bioinformatics
pipelines making it feasible to sequence the genome of GIN rela-
tively quickly, although generating high quality assembled and
annotated genomes is still challenging due to the large size of
GIN genomes (approximately 300–700 Mb, representing an esti-
mated 20,000 protein coding genes) and the high level of polymor-
phism within populations. Of the GIN considered here, most
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tus, sequenced independently from UK and Australian isolates
(Laing et al., 2013; Schwarz et al., 2013). This was achieved using
short read sequencing technologies to provide short DNA
sequences which are then assembled into contigs and scaffolded
by mate pair data. Refinement of the initial H. contortus genome
assembly has involved the use of long-read sequencing, optical
mapping and intensive manual curation, enabling assembly at a
chromosome level (Doyle et al., 2017). This assembly has been
annotated with the inclusion of Iso-Seq data, which generates
full-length cDNA sequences.
Technologies developed for H. contortus genome assembly can
be applied to related GIN including Tel. circumcincta and Tri-
chostrongylus species. Tel. circumcincta genome sequencing and
assembly are in progress at the Wellcome Sanger Institute, UK
and McDonnell Genome Institute, St Louis, USA. Genetic diversity
in the Tel. circumcincta population, and strikingly large genome
size, make this challenging. Genetic variation was previously
observed for H. contortus and is compounded by polyandry, a phe-
nomenon also reported for Tel. circumcincta (Redman et al., 2008;
Gilleard and Redman, 2016). For T. colubriformis, genome sequenc-
ing is in progress at the United States Department for Agriculture
(USDA; USA) (https://www.ars.usda.gov/research/project/?ac-
cnNo=431526). Current sequence data for GIN genomes can be
accessed at the WormBase ParaSite website (https://para-
site.wormbase.org/index.html), which allows comparison of gene
sequences across species, as well as predicted functional informa-
tion based on gene ontology (GO) data. However, the function of
many nematode genes is currently unknown; notably 47% of
nematode gene families lack any functional annotation
(International Helminth Genomes Consortium, 2019). Genome
sequences will allow identification of genes and pathways con-
served across GIN, for rational selection as vaccine candidates.
Transcriptomic data are publicly available for some species of
scour worms and these data are usually generated from the para-
sites at specific developmental stages, living in specific niches or,
in some cases, from individual sexes. For T. colubriformis, transcrip-
tomic data for adult (mixed sex) worms (Cantacessi et al., 2010)
have been deposited in publicly accessible sites (http://www.ne-
matode.net/ and http://research.vet.unimelb.edu.au/gasserlab/in-
dex.html). For T. vitrinus there is less publicly-available
transcriptomic sequence; studies by Nagaraj et al. (2008) and
Nisbet and Gasser (2004) used the same set of 400 sex-specific
adult expressed sequence tags (ESTs) in an early comparative tran-
scriptomic study but few sequences have been added since then. In
contrast to the paucity of EST data for some Trichostrongylus spp.,
there is more transcriptomic data available for Tel. circumcincta
(Nisbet et al., 2008; Menon et al., 2012) and currently on http://ne-
matode.net there are a large number of Tel. circumcincta genes for
which RNAseq expression data are available. Additional, ‘‘niche-
specific” transcriptomes are available: exsheathed L3s (xL3)
exposed to abomasal extracts from immune and non-immune
sheep (Halliday et al., 2012) and mucosal-dwelling (MD) versus
lumen-dwelling (LD) L4 (McNeilly et al., 2017). In this latter study,
transcripts significantly differentially expressed between MD and
LD larvae were identified, of which the majority were up-
regulated in MD larvae and encoded a suite of potentially
immune-regulatory proteins produced by the parasite only when
in intimate contact with the host, which might be exploitable as
vaccine candidates (McNeilly and Nisbet, 2014).
For H. contortus, RNAseq expression data are publicly available
(Laing et al., 2013). Of particular relevance to vaccine development,
a female gut-specific transcriptome identified a suite of gut-
expressed cysteine-type peptidase and cysteine-type peptidase
inhibitors (Laing et al., 2013). Recent differential transcriptomic
analysis in H. contortus has also demonstrated that worms surviv-ing in sheep vaccinated with Barbervax had an increased expres-
sion of genes encoding (non-Barbervax) proteases and regulators
of lysosome trafficking (Sallé et al., 2018). Both publications sup-
port previous research suggesting that gut proteinases, and their
regulators, are strong vaccine candidates (reviewed in Nisbet
et al., 2016).5.2.2. Reverse vaccinology
The traditional design of vaccines was complemented by ‘‘re-
verse vaccinology” (RV) in the mid-late 1990s following the advent
of whole genome sequencing (WGS) of pathogens (Fig. 3). The orig-
inal RV approach used genomics, high throughput recombinant
protein expression and screening in vivo for early antigen discov-
ery. This process has since evolved to ‘‘reverse vaccinology 2.0”
which adds the development of host-specific monoclonal antibody
(mAb) production, B cell repertoire deep sequencing, proteomics
and structure-based antigen design to the original approach (re-
viewed in Rappuoli et al., 2016).
In RV, vaccine candidates are initially identified using in silico
algorithms (e.g. Vaxign, http://www.violinet.org/vaxign/; He
et al., 2010; reviewed in Lew-Tabor and Rodriguez Valle (2016)
to predict open reading frames (ORFs) of surface, membrane or
secreted proteins fromwhole genomes. For this reason, a complete,
assembled, annotated genome is the preferred starting point,
although a deep stage-specific transcriptomic analysis for vaccines
targeting specific developmental stages of GIN might be a reason-
able proxy. These genomic/transcriptomic components of the clas-
sical RV approach are either already available (e.g. in the case of
Haemonchus contortus), are in development (Tel. circumcincta, T.
colubriformis) or are lacking (T. vitrinus) (recently reviewed by Jex
et al. (2019)). It should be noted, however, that most in silico pre-
diction algorithms have been developed with viral or bacterial
pathogens, but not helminths, in mind. The other components of
classical RV – capacity to produce recombinant proteins in high
throughput, appropriate immunogenic and protective forms, and
robust animal models for the testing of candidate antigens – are
both available for testing of prototype vaccines against scour
worms. Recently, significant progress has been made in the use
of RV approaches to develop vaccines against the cattle tick (Rhipi-
cephalus microplus) and the Australian paralysis tick (Ixodes holocy-
clus) (Lew-Tabor and Rodriguez Valle, 2016; Tabor, 2019).
SophisTICKated anti-tick vaccines- cattle tick and Australian paral-
ysis tick. Proceedings of the UK and International Veterinary Vacci-
nology Network Conference, London 9–10th January 2019) with
the vaccine for the former having gone through 12 years of antigen
discovery, bioinformatics, in vitro immune screening and in vitro
tick feeding followed by seven challenge trials.
The large genomes of parasitic helminths and the potential that
recombinant vaccine candidates may need to be expressed in
eukaryotic systems for optimal efficacy both make the traditional
RV route cumbersome for parasitic worms (Merrifield et al.,
2016). Nevertheless, significant progress has been made in the
use of RV to identify vaccine antigens from Schistosoma mansoni
through in silico prediction of immunogenic epitopes of trans-
membrane proteins coupled with selection of these epitopes for
high binding affinities for host MHC class II molecules (Oliveira
et al., 2016; de Souza et al., 2018). Algorithms developed for
human MHC molecules could potentially help identify immuno-
genic molecules from sheep parasites, although algorithms specific
for small ruminant MHC molecules are likely to be more helpful.
Reverse vaccinology 2.0 is considerably more advanced in
human vaccine development than in veterinary species. Because
most licensed vaccines act by inducing protective antibody
responses, most of the key breakthroughs for RV 2.0 have revolved
around antibody technologies. The key elements of the approach
Fig. 3. Reverse vaccinology approach for novel vaccine development for scour worms, involving similar approaches and processes from the parasite genomes utilised by
Tabor (2017, 2019) for the tick vaccine. EV, extracellular vesicles; MHC, major histocompatibility complex.
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recent years (reviewed in Rappuoli et al., 2016) have been:
 development of recombinant mAbs or their antigen binding
fragments from cloned B cells derived from immunised (pro-
tected) or convalescent (immune) individuals. These can then
be used to screen for their neutralising ability against the patho-
gen (requiring an in vitro assay, see Section 6.5) and to identify
the specific epitopes that they bind (see Section 6.2.3);
 high throughput, deep sequencing transcriptomic analyses to
analyse the B cell repertoire, understand antibody maturation
following infection or immunisation and devise strategies to
prime B cell precursors expressing germline-encoded
antibodies;
 mapping of conformational epitopes through 3-D analysis of
their interactions with the antigen binding fragments of neu-
tralising antibodies;
 new computational approaches to understand the structural
and immunological data to design novel vaccines to stimulate
specific immunological responses to protective epitopes.
5.2.3. Epitope mapping and peptide arrays
The likely requirement for multiple recombinant antigens to be
co-administered to effectively control complex eukaryotic parasitic
organisms by vaccination (e.g. see Makepeace et al., 2009; Nisbet
et al., 2013) makes the antigen discovery, production and commer-cialization processes challenging. A potential solution to the latter
two issues is to map the most immunogenic epitopes of individual
antigens and then to administer these as concatemerised peptides.
Using web-based tools, B and T-cell epitopes can be predicted in
silico from the protein sequence of potential vaccine antigens
(e.g. the Immune Epitope Database and Analysis Resource server
at https://www.iedb.org/ and/or the NetCTL server http://www.
cbs.dtu.dk/services/NetCTL/). Empirical evidence to underpin the
in silico epitope mapping of linear B cell epitopes can be generated
using immune or convalescent sera to probe overlapping peptides
representing the entire protein either on peptide arrays or in ELISA
plate format (e.g. see Dobrut et al., 2018) whereas T cell epitope
mapping can be achieved using peptide libraries coupled with ELI-
Spot assays (e.g. see Zhao et al., 2018).
An epitope mapping strategy is being pursued for parasites (e.g.
Trypanosoma cruzi; Khatoon et al., 2018) where immunogenic epi-
topes of secretory and membrane proteins were predicted and pro-
duced as a synthetic construct, together with molecular docking
analysis to optimize the interaction between TLR-2 and TLR-4
receptors and the synthetic vaccine. In parasitic nematodes,
Immanuel et al. (2017) described the design, synthesis, and efficacy
testing of short peptide epitopes from antigens of filarial nema-
todes constructed as a ‘‘multiple antigen peptide” on an inert
lysine core. In jirds, the synthetic vaccine produced high levels of
antigen-specific antibody, a cellular response and significant levels
of protection (Immanuel et al., 2017).
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Historically, many candidate antigens were differentially
identified using serological reagents from small numbers of
immune versus susceptible sheep (Emery, 1996; Nisbet et al.,
2016) in two-dimensional (2-D) immunoblotting. A more compre-
hensive immune profiling strategy is summarised in Fig. 3, starting
with a comprehensive annotated genome, stage-specific transcrip-
tome, proteome and glycome from the parasite to inform all down-
stream analyses.
The downstream analyses in such a strategy could employ
immunoaffinity chromatography to separate immunoreactive par-
asite molecules from each parasitic stage, followed by mass spec-
trometry to identify immunoreactive proteins, genetic variants
and glycans within these molecules (as described in Ellis et al.,
2014). An additional/alternative approach is to generate high den-
sity peptide microarrays, which can now represent up to 2 million
peptides on a single chip (Hansen et al., 2017; Østerbye and Buus,
2015). Peptides would be selected using in silico RV approaches to
select ORFs encoding membrane or secreted proteins and arrays
screened with antibody from multiple immune-protected sheep
to precisely define potentially protective linear B cell epitopes
(and by extension antigens targeted by CD4+ T cell responses). A
similar approach can also be taken to interrogate glycan antibody
reactivity in which microarrays consisting of glycans isolated from
different parasite life-stages are used for antibody screening (Yang
et al., 2018). More focussed, molecule-specific ELISA, peptide and
glycan arrays can then be developed to quantify the response to
each molecule by immune sheep (using reagents from biobanks,
resource flocks or from trials) with ranked FWECs or worm burden
data. Sophisticated statistical methods, especially generalized lin-
ear mixed modelling, will rank molecules by their influence on
resistance to infection.
5.3. Antigen validation by gene silencing
The multiple approaches described above can help select vac-
cine candidates but validation of these is important for any vaccine
development pipeline. This could involve gene knockdown and
analysis of resulting phenotypes (e.g. larval arrest, lethality)
in vitro. RNAi, where exogenously delivered double-stranded
RNA (dsRNA) targets the corresponding mRNA for degradation,
has been shown to function very effectively in C. elegans by soaking
worms in dsRNA, feeding on bacteria expressing dsRNA or microin-
jection of dsRNA. However, in other nematode species, soaking and
feeding are far less effective (Félix, 2008). Using various delivery
methods, RNAi has been shown to silence some genes in GIN
including H. contortus (Geldhof et al., 2006; Kotze and Bagnall,
2006; Blanchard et al., 2018; Menez et al., 2019), Tel. circumcinta
(Tzelos et al., 2015) and T. colubriformis (Issa et al., 2005) (Table 3).
By targeting a range of genes, those expressed in the parasite intes-
tine, amphids and excretory system could be silenced, while others
were refractory (Samarasinghe et al., 2011). This indicated that for
L3s, RNAi is useful for testing the function of genes expressed in
sites accessible to the trigger dsRNA but, using current technology,
is not suitable for high-throughput functional genomics. In vitro
RNAi screening would be the ideal approach and reduce the ethical
and cost concerns of in vivo testing. However for some parasite
genes, such as those involved in the host-parasite interaction
(e.g. mediating host immunosuppression) or required only by
developmental stages present within the host, determining effects
in vivo, or with improved in vitro culture conditions that mimic the
host environment, would be required. Notably, RNAi of the H11
gene in H. contortus L3s in vitro prior to infection of sheep resulted
in a 57% reduction in FWECs, 40% reduction in worm burden and
64% decrease in aminopeptidase activity (Samarasinghe et al.,
2011), supporting use of RNAi for candidate gene identification.The RNAi pathway is functional in GIN but improvements to the
reliability and robustness of silencing and phenotypic or proteomic
analysis are needed for this to be applied as a potential vaccine-
screening platform (Geldhof et al., 2007; Britton et al., 2016).
Stable transfection of nematodes with viral vectors expressing
dsRNA to parasite genes is one route to improve on the delivery
and persistence of RNAi. Transduction with lentiviral constructs
expressing short hairpin RNAs has been shown to induce specific
gene silencing and phenotypic effects in S. mansoni eggs (Hagen
et al., 2014); similar technology is being investigated for the mouse
GIN Nippostrongylus brasiliensis and may progress RNAi for scour
worms (https://gtr.ukri.org/projects?ref=BB%2FS001085%2F1).
An alternative approach being widely applied in mammalian
systems and C. elegans is CRISPR/Cas9 gene editing. In C. elegans,
CRISPR/Cas9 gene knockout is highly efficient and specific (Chen
et al., 2013). This technology was successfully applied to the
human GIN Strongyloides stercoralis (Gang et al., 2017; Lok et al.,
2017). Efficient delivery of the guide RNA and Cas9 gene/protein
are the main hurdles to this being adopted more widely in parasitic
nematodes. Strongyloides spp. have a free-living cycle and free-
living adult female worms can be transfected by microinjection
in a similar manner to C. elegans (Lok et al., 2017). Effects of
CRISPR/Cas9 gene silencing are then examined in the F1 generation
following mating. Importantly, the findings of Gang et al. (2017)
suggest that in S. stercoralis, homozygous gene deletion occurred
and was detectable in the F1 generation, without the need for fur-
ther parasite passage. Although microinjection of individual
worms is not a high-throughput approach and not applicable to
all nematodes, the use of viral vectors or nanoparticles to deliver
CRISPR/Cas9 (reviewed in Lino et al., 2018), combined with
improved in vitro culture systems for parasite maintenance (see
Section 5.5), may provide a route for robust gene silencing in vet-
erinary GINs.
5.4. Translational silencing
A novel methodology using peptide conjugated phosphorodi-
amidate morpholino oligomers (PPMOs) allows determination of
the phenotype resulting from protein knockdown. PPMOs are
non-ionic DNA analogues attached at the 30-end to a peptide which
allows transmembrane movement (Li and Morcos, 2008). Transla-
tion of a specific target mRNA in the cell or organism is blocked
through Watson/Crick base-pairing of the PPMO with the 50end
of the target mRNA, physically preventing assembly of the ribo-
some at the initiation codon (Summerton, 1999). This post-
transcriptional silencing allows assessment of whether these pro-
teins are essential and potentially good targets for drugs or vac-
cines. PPMO-mediated translational silencing may be a promising
alternative to RNAi and Witola et al. (2016) used this technique
to silence phosphoethanolamine methyltransferase expression in
adult H. contortus in vitro, resulting in a measurable phenotype.
Several components are required for successfully carrying out RNAi
or PPMO-mediated silencing:
 transcriptomic knowledge to ensure that the target mRNA is
expressed in the stage being investigated and that the sequence
of the dsRNA or PPMO oligomer is unique to the target gene;
 a method to measure knockdown of the gene or protein (e.g.
quantitative (q)PCR, quantitative immunoblotting, qProteomics,
enzyme assay);
 a physiologically-relevant method to keep the worms alive
in vitro during incubation and downstream phenotypic
analysis;
 a thorough assessment of whether the control dsRNA or PPMO
(with no-target transcripts in the organism) and any carrier sol-
vents have detrimental effects on the worms in the assay.
Table 3
Summary of gene silencing in Haemonchus contortus (Hco), Teladorsagia circumcincta (Tci) and Trichostrongylus colubriformis (Tco).
Species Stage Target gene(s) Evaluation Reference
Hco L3, L4, adult reduced L3 motility b-tubulin Reduced mRNA, reduced L4 development Kotze et al., 2005
L1-L3 b-tubulin
GATA TF
Hsp70
Cathepsin L
ATPase
Superoxide dismutase
Paramyosin
Collagen
Intermediate filament
COPII component
Calcium binding protein
Reduced mRNA for some targets Geldhof et al., 2006
L3 H11
ASP-1
b-tubulin
GTPcyclohydrolase
Aquaporin apq-2
Helicase phi-10
Transcription factor ceh-6
Chloride channel exc-4
Ribosomal genes
Reduced mRNA for some targets Reduced
in vivo survival H11 RNAi
Samarasinghe et al., 2011
L1, L3, adult Ubiquitin
b-tubulin
paramyosin
Tropomyosin
ATPase vha-19
Mechanoreceptor
noah-1
mitr-1
galactopyranose
mutase glf-1
pat-12
Reduced mRNA for some targets Reduced
viability following RNAi feeding
Zawadzki et al., 2012
L2 unc-38
unc-63
Unco-ordinated motility Blanchard et al., 2018
acetylcholine receptor acr-8 Reduced levamisole sensitivity Blanchard et al., 2018
nuclear hormone receptor nhr-8 Increased ivermectin sensitivity Menez et al., 2019
Adult aPMT1&2
Phosphoethanolamine
N-methyltransferase
Reduced protein& reduced viability Witola et al., 2016
Tci L3 ASP Reduced mRNA Tzelos et al., 2015
Tco L1 Tropomyosin
Ubiquitin
Delayed development to L3 Issa et al., 2005
a All studies carried out by RNAi except this study by Witola et al. which used morpholino oligomers TF, GATA transcription factor; hsp70, heat shock protein 70; ASP-1,
activation-associated secretory protein 1; pat, paralysed arrest at two-fold; unc, unco-ordinated.
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with scour worms as PPMOs require to be at relatively high con-
centrations in the culture medium (90 mM for work published by
Witola et al. (2016)). Preliminary work with xL3s Tel. circumcincta
has suggested that micromolar concentrations of a control and a
gene-specific PPMO are both toxic to this stage of the worm (Nisbet
et al., unpublished data).5.5. In vitro culture
Improved in vitro culture of GIN should enable better delivery
of RNA or DNA for gene silencing or screening for effective neutral-
izing antibodies to establish vaccine screening platforms. Ideally,
effects on worm motility, moulting or survival could be detected
using automated systems over longer timespans than in current
drug screens. Previous work reported in vitro development of H.
contortus infective larvae to reproducing adult worms using abo-
masal extracts (Stringfellow, 1986). More recent studies have used
cell co-culture to achieve improved development of GIN. For exam-
ple, co-culture with Caco2 cells, a human gut epithelial cell line
previously used for T. spiralis culture (Gagliardo et al., 2002), pro-
motes development of H. contortus L3s to L4 stage (Britton et al.,2016), while the human colonic cell line HT-29 supports develop-
ment of T. colubriformis L3 (Andronicos et al., 2012).
An ‘‘in vitro direct challenge” (IVDC) method was developed to
examine the initial immune exclusion/prompt rejection mecha-
nism operating in the abomasa of sheep immune to Tel. circum-
cincta (Jackson et al., 2004) or H. contortus (Kemp et al., 2009).
Abomasal tissue explants were maintained in buffer in a high oxy-
gen concentration, then challenged with xL3s. xL3s that penetrated
gastric glands or had been excluded/rejected were then recovered.
While this technique is unlikely to maintain parasitic stages of the
nematodes for periods longer than a few hours, the methodology
was adapted by Nisbet et al. (2009) to test whether antibodies to
Tel. circumcincta vaccine candidate Tci-SAA-1 were able to inhibit
the larvae from establishing in abomasal explants from
helminth-naïve lambs.
Recent successful development of intestinal organoids (Sato
et al., 2011; Powell & Behnke, 2017; Hamilton et al., 2018) provides
another in vitro technology that may support GIN development for
target screening. Intestinal organoids (mini-guts) are derived from
single stem cells isolated from the intestinal crypts. These LGR5+
stem cells divide and differentiate in vitro under suitable condi-
tions (with growth factors) to produce all the cells characteristic
of gut epithelium including goblet cells, enterocytes, Paneth cells,
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generated from the gastric epithelium for the abomasal parasites.
Organoids can be serially passaged long-term and may provide a
more physiological epithelium culture system in which parasite
larvae may be maintained and host-parasite interactions exam-
ined. Duque-Correa et al. (2020) are using tissue organoids to study
host-parasite interactions and parasite larval development, partic-
ularly for Trichuris muris. GIN infective larvae are larger than T.
muris,making their introduction into 3-D organoid structures more
difficult. However, once established, 3-D organoids can also be cul-
tured as a 2-D epithelial layer, which would enable greater access
and penetration of parasites. This potentially provides a physiolog-
ical system to develop and maintain veterinary nematodes for vac-
cine candidate screening. Alternatively, ILC2 cells involved in Th2
responses in gut (helminths) and lungs (Neill et al., 2010) may pro-
vide an additional means to screen for the developmental intrica-
cies of host-parasite reactivity.Fig. 4. Simulations of vaccines with varying levels of efficacy and differing
proportions of host responders on the numbers of deaths from scour worms in a
flock. Deaths occur in lambs when worm numbers reach 2500 (modified from
Barnes et al., 1995).5.6. microRNAs and extracellular vesicles
In addition to RNAi-mediated gene silencing, nematodes
express small regulatory microRNAs (miRNAs) that silence genes
post-transcriptionally. In C. elegans, some of these miRNAs play
essential roles in regulating development and responses to envi-
ronmental stress (reviewed in Britton et al., 2014). Some of the
miRNAs present in C. elegans are conserved in veterinary GIN
(Winter et al., 2012; Gu et al., 2017), and likely act to regulate
development and metabolism. While miRNAs may themselves be
targets for therapeutic intervention (Britton et al., 2014), determin-
ing the pathways they regulate as parasites develop within the
host has the potential to identify novel control targets (Marks
et al., 2019).
Further to regulating endogenous genes within the parasite,
miRNAs are also released from GIN including Tel. circumcincta, H.
contortus (Gu et al., 2017) and Heligmosomoides polygyrus (Buck
et al., 2014). miRNAs have been sequenced from in vitro ES prod-
ucts, both in the supernatant and in extracellular vesicles (EV) iso-
lated from ES by differential ultracentrifugation (Buck et al., 2014;
Gu et al., 2017). Parasite-derived miRNAs have also been identified
in host plasma following filarial infections, suggesting that they are
also released in vivo (Tritten et al., 2014). Importantly, secreted
miRNAs present in EV have been shown to modulate host immune
response genes, suggesting that they may function at the host-
parasite interface to promote parasite survival and/or suppress
immune-mediated damage (Buck et al., 2014). Recently, the pro-
teome of EVs released from Tel. circumcincta has been characterised
and includes a number of putative immunomodulatory proteins
which are targeted by both IgA and IgG antibodies from infected
sheep (Tzelos et al., 2016). Targeting EV through vaccination may
therefore neutralize immunoregulatory effects and enhance
immunity. Indeed, recent vaccination studies in mice using 1.5–
3 lg of EVs prepared from ES products of cultured adult H. poly-
gyrus or T. muris nematodes and inoculated without adjuvant,
reduced worm burden by approximately 50%, by inducing antibod-
ies that promote uptake and processing by antigen presenting cells
(APC) (Coakley et al., 2017; Shears et al., 2018). EVs from T. muris
contained approximately 125 proteins, such that through their
uptake by APC, EVs may provide a novel vaccine formulation
(Shears et al., 2018).6. Field integration and evaluation of vaccines
Vaccines against sheep nematodes are envisaged as a compo-
nent of IPMs. Vaccination suppresses pasture contamination with
worm eggs, with subsequent reductions in worm burdens. Fortu-nately, ecological research over many years has provided a detailed
understanding of seasonal patterns for the major species in the
major ‘‘type” environments (e.g. O’Connor et al., 2006), which will
serve as the basis for computer simulation modelling of optimal
vaccination schedules for various locations, followed by in-field
validation.
One of the key questions remains, ‘‘How much protection is suf-
ficient for my vaccine?” Several models are available to test
hypotheses (Dobson et al., 2011; de Cisneros et al., 2014;
Laurenson and Kahn, 2018). Previous modelling studies (exempli-
fied in Fig. 4) indicated that prevention of deaths in weaners with
concomitant reductions in pasture L3 could be achieved with vac-
cines which gave 70–80% protection (reduced FWECs) in 80% of
vaccinated animals. Death was presumed to occur with Tri-
chostrongylus worm burdens of >2500 (Fig. 4). These simulations
should be extended to incorporate the various vaccine efficacies
in concert with additional interventions normally associated with
IPMs – for example the interactions between vaccine efficacy and
nutrition (or strategic anthelmintic use) to give adequate protec-
tion. This will need empirical data from pen and field studies in
which vaccines of known efficacy are tested, even if their protec-
tive capacity is lower than the previously determined minimum
thresholds. At this point, since current IPM utilise seasonal pasture
L3 levels from field data that is more than 30 years old, no mod-
elling on the effects of vaccination on pasture L3s has been done.7. Conclusions
The development, formulation and delivery of a successful GIN
vaccine requires an understanding of three major components (see
Fig. 5):
(i) the protective responses to be induced by the vaccine;
(ii) the most appropriate suite of molecules that induce effective
immunity;
(iii) the ability of different vaccine formulations (+/ adjuvants)
to induce potential protective immune responses against
GINs in sheep mucosa.
To address (i): Th2 responses are protective against scour
worms in sheep (see Section 2). However, the main targets of this
immune response in the worms are poorly understood at this stage
andmethods for inducing the appropriate parts of the immune sys-
Fig. 5. A generalised overview of the integrated process pipeline for scour worm vaccines. The three areas of (1) HxP (host by parasite) interaction; (2) antigen discovery and
validation and (3) vaccine formulation and performance come together to formulate verified protective antigens (2) into the most effective vaccine preparation (3) to deliver
and elicit the protective response(s) identified from (1). Tel c/Tc, Teladorsagia circumcincta/ Trichostrongylus colubriformis.
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dynamic investigation of the host-parasite interaction in vivo dur-
ing the 3–6 weeks taken to develop immunity and worm patency
(Fig. 5).
To address (ii): many vaccine ‘‘candidate” antigens have been
identified, purified and trialled as native or recombinant vaccines
against Tel. circumcincta and T. colubriformis; there is no shortage
of potential antigens. However, with a long-term approach similar
to the successful Cattle Tick vaccine using RV from an annotated
genome, a new opportunity is available for scour worms. Vaccines
for scour worms may require several components to be developed
through a RV approach and rationally integrated into the vaccine
development program (i-iii above; see Section 5). Once these anti-
gen/ pathway targets in the worms have been identified (i), a
screening method is needed to allow the identification of the best
targets from potentially large numbers of candidates at the start of
the process. Currently this would rely on screening in the animals
but the development of novel methods to do this in the laboratory
would be faster, reduce potential ethical limitations and be more
cost-effective, and a set of potential techniques to address this is
presented in the review (see Section 5). A prerequisite is an appre-
ciation of what has already been attempted for these and other
species and what current and emerging technologies might be
employed to produce and evaluate novel vaccines. These include
new ‘omics’ technologies as well as antigen validation by methods
such as gene knock-out or silencing. Each of these aspects is
addressed in the review and, although there is substantial knowl-
edge in most of these areas, fundamental gaps exist in knowledge,
available resources and technologies (above) to allow a fully func-
tional RV approach.
To address (iii): we know how to induce high levels of ‘‘protec-
tive” antibody in sheep using a range of ‘‘immunostimulants” or
adjuvants (see Section 3). What is not known is exactly how the
host-parasite interaction over several weeks manages to generate
the protective immunity to prevent parasitism. In the absence of
definitive information of the (stage-specific) protective responseor its induction in ruminants, most vaccines containing purified
or recombinant antigens have used an empirical approach. We
do not know how to induce mucosal immunity with a vaccine.
While we recommend the kinetic analysis of the host-parasite
interaction to provide insights into (i), a similar approach is needed
to provide information on the effects of vaccine formulations on
mucosal immunity so that we can formulate any potential antigens
into a vaccine that induces the responses identified as protective
by (i); thus integrating the three approaches needed for optimising
vaccine success. A meta-analysis of the inductive capabilities of
current vaccine adjuvants for ruminants may assist here.
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